Teladoc Health Inc (NYSE:TDOC) insider Lewis Levy sold 2,025 shares of Teladoc Health stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $80.50, for a total value of $163,012.50. Following the completion of the transaction, the insider now owns 5,655 shares in the company, valued at $455,227.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Lewis Levy also recently made the following trade(s):

  • On Tuesday, October 15th, Lewis Levy sold 675 shares of Teladoc Health stock. The shares were sold at an average price of $70.00, for a total value of $47,250.00.
  • On Tuesday, October 1st, Lewis Levy sold 1,350 shares of Teladoc Health stock. The shares were sold at an average price of $67.79, for a total value of $91,516.50.
  • On Thursday, September 12th, Lewis Levy sold 675 shares of Teladoc Health stock. The shares were sold at an average price of $70.00, for a total value of $47,250.00.

Shares of Teladoc Health stock traded up $1.17 during trading on Wednesday, reaching $80.05. The company’s stock had a trading volume of 903,243 shares, compared to its average volume of 1,346,980. The company has a quick ratio of 6.55, a current ratio of 6.55 and a debt-to-equity ratio of 0.44. The company has a market cap of $5.79 billion, a price-to-earnings ratio of -55.59 and a beta of 1.40. Teladoc Health Inc has a 1-year low of $42.08 and a 1-year high of $86.30. The company has a 50-day simple moving average of $76.85 and a two-hundred day simple moving average of $67.27.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.12. The firm had revenue of $137.96 million during the quarter, compared to analysts’ expectations of $136.46 million. Teladoc Health had a negative return on equity of 11.23% and a negative net margin of 20.15%. The business’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) EPS. As a group, analysts anticipate that Teladoc Health Inc will post -1.55 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Westside Investment Management Inc. acquired a new stake in shares of Teladoc Health in the 2nd quarter worth $26,000. CNB Bank boosted its position in shares of Teladoc Health by 100.0% in the 3rd quarter. CNB Bank now owns 400 shares of the health services provider’s stock worth $27,000 after purchasing an additional 200 shares in the last quarter. Capital Investment Advisory Services LLC boosted its position in shares of Teladoc Health by 800.0% in the 3rd quarter. Capital Investment Advisory Services LLC now owns 450 shares of the health services provider’s stock worth $30,000 after purchasing an additional 400 shares in the last quarter. Marshall Wace North America L.P. acquired a new stake in shares of Teladoc Health in the 1st quarter worth $35,000. Finally, Tradewinds Capital Management LLC lifted its position in Teladoc Health by 186.0% during the 2nd quarter. Tradewinds Capital Management LLC now owns 615 shares of the health services provider’s stock worth $41,000 after acquiring an additional 400 shares during the period.

TDOC has been the topic of a number of analyst reports. Royal Bank of Canada initiated coverage on Teladoc Health in a report on Wednesday, November 27th. They issued an “outperform” rating and a $100.00 price target on the stock. Zacks Investment Research downgraded Teladoc Health from a “buy” rating to a “hold” rating and set a $89.00 price target on the stock. in a report on Wednesday, November 27th. Stifel Nicolaus initiated coverage on Teladoc Health in a report on Monday, November 25th. They issued a “hold” rating and a $83.00 price target on the stock. Oppenheimer set a $83.00 price target on Teladoc Health and gave the company a “buy” rating in a report on Friday, September 6th. Finally, ValuEngine upgraded Teladoc Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $81.73.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Elliott Wave Theory

Insider Buying and Selling by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.